Indeed, various studies in prostate cancer cell lines have shown that hydralazine restored the expression of silence genes and functioned synergistically with the androgen receptor antagonist enzalutamide and the histone deacetylases inhibitor (HDACi) panobinostat to exert anti-tumour effects [76,77,78]. Here, AR is linked to prostate cancer.